Recruiting NCT07261306
Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Methotrexate, Tofacitinib.
- Who it may be relevant to
- Registry conditions: Psoriasis. Basic parameters: 18 years — 70 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Pakistan
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Psoriasis is a chronic inflammatory dermatoses which include well demarcated scaly erythematous plaques on whole body including scalp role of methotrexate vs tofacitinib is compared in this study
Detailed description
Comparison between safety and efficacy of oral methotrexate and tofacitinib in chronic plaque psoriasis is to be determined in this study
Interventions
- Drug Methotrexate
Methotrexate is an antifolate drug work by inhibiting enzyme dihydrofolate reductase and inhibit cell proliferation and play a role in psoriasis treatment - Drug Tofacitinib
Tofacitinib is janus kinase inhibitor and have role in psoriasis
Primary outcome measures
- Efficacy Achievement [Time frame: Baseline to Week 12 of treatment]
Secondary outcome measures (1)
- Percentage Reduction in PASI Score [Time frame: From Baseline to Week 12]
Eligibility criteria
Inclusion criteria
- Patients aged 18- 70 years of either gender.
- Only patients with Psoriasis Area and Severity Index (PASI) score of 10 or above, and/or Body Surface Area (BSA) involvement of 10% or more, will be included.
- Duration of plaque psoriasis for at least 6 months prior to the study.
- Psoriasis that has not shown adequate response to topical therapies
Exclusion criteria
- Individuals with other forms of psoriasis or other significant dermatological conditions that might interfere with the assessment of psoriasis.
- Participants currently receiving systemic corticosteroids, biologics, or any other immunosuppressive agents within 4 weeks prior to the start of the study will be excluded.
- Known hypersensitivity or contraindications to either methotrexate or tofacitinib.
- History of significant liver, kidney, hematologic/bleeding disorder, gastrointestinal/acid peptic disease, or immune system disorders.and any history of tuberculosis and malignancy.
- Pregnant or lactating women will not be eligible for the study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Pakistan · 1 center
- Lahore general hospital — Lahore
Identifiers
NCT: NCT07261306 · Derma LGH